Apellis Pharmaceuticals, Inc. faces a Sell rating amid revenue stagnation, Syfovre challenges, and uncertain long-term profit ...

Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing ...

In 2023, Japan's market size for Paroxysmal Nocturnal Hemoglobinuria therapeutics was around USD 88.5 million, with expectations of growth throughout the forecast period (2024-2034). Projections ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the best upside stocks to buy now. On November 12, Apellis Pharmaceuticals announced that a post hoc analysis of the Phase 3 GALE extension study ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ranks among the most oversold biotech stocks to invest in. On November 3, Mizuho maintained its Neutral rating for Apellis Pharmaceuticals Inc. (NASDAQ:APLS) ...

Fintel reports that on November 3, 2025, Mizuho maintained coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a Neutral recommendation. Analyst Price Forecast Suggests 87.06% Upside As of ...

Apellis Pharmaceuticals (NASDAQ:APLS) is preparing to release its quarterly earnings on Thursday, 2025-10-30. Here's a brief overview of what investors should keep in mind before the announcement.

11 analysts have shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes ...

WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter ...